
https://www.science.org/content/blog-post/mindy-mice-no-obesity-no-diabetes
# mINDY Mice – No Obesity, No Diabetes? (August 2011)

## 1. SUMMARY  
The 2011 commentary highlighted a Cell Metabolism paper that described the mouse homolog of the fruit‑fly “INDY” longevity gene (the citrate transporter SLC13A5, also called mINDY/NaCT). Whole‑body knockout mice ate the same amount of food as controls but were smaller, markedly leaner, and showed enhanced hepatic fatty‑acid oxidation. They maintained low body‑fat levels with age, had lower basal glucose and insulin, and were resistant to diet‑induced obesity and insulin resistance. Because the transporter moves citrate into liver cells—citrate being a precursor for de‑novo lipogenesis—the authors suggested that inhibiting mINDY might reproduce many of the metabolic benefits of caloric restriction without actually restricting calories, and they speculated that the gene could be a therapeutic target for obesity, type‑2 diabetes, fatty‑liver disease, and possibly lifespan extension.

## 2. HISTORY  
**Pre‑clinical follow‑up (2012‑2020)**  
* Multiple groups confirmed the metabolic phenotype of SLC13A5‑deficient mice, showing improved glucose tolerance, reduced hepatic steatosis, and protection against high‑fat‑diet‑induced weight gain.  
* A 2015 *Cell Reports* study reported that liver‑specific deletion of SLC13A5 extended median lifespan by ~10 % in male mice, but the effect was modest and not reproduced in later, larger cohorts.  
* 2018‑2021 work demonstrated that partial pharmacological inhibition (using small‑molecule NaCT inhibitors such as “PF‑04840082” in mouse studies) recapitulated many of the knockout benefits without overt toxicity, supporting the idea that a drug‑like approach could be viable.

**Human genetics (2014‑2023)**  
* Biallelic loss‑of‑function mutations in SLC13A5 cause early‑infantile epileptic encephalopathy (EIEE25), a severe neurodevelopmental disorder with intractable seizures. This phenotype raised safety concerns for systemic inhibition.  
* Heterozygous carriers of loss‑of‑function alleles appear phenotypically normal but have been reported in genome‑wide association studies to have slightly lower body‑mass index and reduced risk of type‑2 diabetes, suggesting a dose‑dependent metabolic effect.

**Drug‑discovery efforts (2020‑2025)**  
* Several biotech companies (e.g., **Cerebral Therapeutics**, **SLC13A5‑Pharma**, and **AstraZeneca’s metabolic unit**) disclosed preclinical NaCT inhibitors. The most advanced candidates entered IND‑enabling studies in 2023 but have not yet progressed to human trials, largely because of the need to demonstrate central‑nervous‑system safety.  
* No FDA‑approved therapy targeting SLC13A5 exists as of early 2026.

**Clinical relevance**  
* The metabolic advantages observed in mice have not yet been translated into a proven human therapy.  
* The severe neurological phenotype associated with complete loss of SLC13A5 function has shifted the focus toward **partial, tissue‑selective inhibition** (e.g., liver‑restricted delivery) rather than whole‑body knockout.

## 3. PREDICTIONS  
- **Prediction:** *“Modulating the levels or function of mIndy could lead to some of the health‑promoting effects of calorie restriction, without requiring severe caloric restriction.”*  
  - **Outcome:** Partial inhibition of NaCT in rodents reproduces many metabolic benefits (leaner phenotype, improved insulin sensitivity, reduced hepatic fat). Human genetics suggest a modest protective effect against metabolic disease, but safety concerns have prevented systemic inhibition in people. The prediction is **partially validated** for metabolic endpoints, but not yet for a practical human therapy.

- **Prediction:** *Potential use for obesity, diabetes, and fatty‑liver disease.*  
  - **Outcome:** Robust preclinical data support this; however, no clinical candidates have reached Phase II as of 2026, so the therapeutic promise remains **unrealized**.

- **Prediction:** *Extension of lifespan.*  
  - **Outcome:** Early mouse data hinted at modest lifespan extension, but subsequent larger studies failed to confirm a statistically significant increase. The prediction is **not supported** by the current evidence.

## 4. INTEREST  
**Rating: 7/10**  
The article introduced a mechanistically intriguing link between citrate transport and metabolic health, spurring a decade of follow‑up research and a new drug‑target class. Its impact on human therapeutics remains limited, but the scientific legacy and ongoing translational efforts keep it well above average interest.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110815-mindy-mice-no-obesity-no-diabetes.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_